Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 7/20 | 0.61 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | RYR2 | Q92736 | 1/20 | 0.37 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.37 |
| ▸ | TPSD1 | Q9BZJ3 | 1/20 | 0.37 |
| ▸ | TPSG1 | Q9NRR2 | 1/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
| ▸ | HTR2B | P41595 | 1/20 | 0.35 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.34 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.34 |
| ▸ | CD44 | P16070 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
| ▸ | PARP1 | P09874 | 1/20 | 0.33 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1038858 | 0.82 | PNMT (0.56) | PNMTTPSAB1TPSD1TPSG1ITGB3 | |
| SCHEMBL1444085 | 0.79 | PNMT (0.61) | PNMTKCNH2TPSAB1TPSD1TPSG1 | |
| SCHEMBL7527801 | 0.78 | PNMT (0.51) | PNMTKCNH2TPSAB1TPSD1TPSG1 | |
| Hydrochloric Acid SCHEMBL1443367 | 0.78 | PNMT (0.60) | PNMTKCNH2TPSAB1TPSD1TPSG1 | |
| SCHEMBL3053106 | 0.77 | PNMT (0.50) | PNMTKCNH2TPSAB1TPSD1TPSG1 | |
| SCHEMBL9471965 | 0.76 | PNMT (0.54) | PNMTKCNH2TPSAB1TPSD1TPSG1 | |
| SCHEMBL15071934 | 0.76 | PNMT (0.54) | PNMTKCNH2TPSAB1TPSD1TPSG1 | |
| SCHEMBL18822929 | 0.76 | PNMT (0.54) | PNMTKCNH2TPSAB1TPSD1TPSG1 | |
| SCHEMBL6424327 | 0.76 | PNMT (1.00) | PNMTTPSAB1TPSD1TPSG1CD44 | |
| Hydrochloric Acid SCHEMBL14141606 | 0.75 | PNMT (0.52) | PNMTKCNH2TPSAB1TPSD1TPSG1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9169265-B2 | Process for preparing pharmaceutical compounds and intermediate compounds | EGIS GYOGYSZERGYAR NYILVANOSAN MUKODO RESZVENYTARSASAG (HU) | 2015-10-27 | — | — | US | disclosed |
| US-20130030183-A1 | PROCESS FOR PREPARING A PHARMACEUTICAL COMPOUND | EGIS GYOGYSZERGYAR NYILVANOSAN MUKODO RESZVENYTARSASAG (HU) | 2013-01-31 | — | — | US | disclosed |
| US-20120330018-A1 | PROCESS FOR PREPARING PHARMACEUTICAL COMPOUNDS AND INTERMEDIATE COMPOUNDS | EGIS GYOGYSZERGYAR NYILVANOSAN MUKODO RESZVENYTARSASAG (HU) | 2012-12-27 | — | — | US | disclosed |
| WO-2012052788-A1 | METHOD FOR PREPARING PHARMACEUTICALLY ACTIVE INGREDIENT AND INTERMEDIATES THEREOF | EGIS GYÓGYSZERGYÁR NYILVÁNOSAN MŰKÖDŐ RÉSZVÉNYTÁRSASÁG (HU) | 2012-04-26 | — | — | WO | disclosed |
| WO-2011110219-A1 | A PROCESS FOR MAKING PRASUGREL | SYNTHON BV (NL) | 2011-09-15 | — | — | WO | disclosed |
| WO-2011077174-A1 | PROCESS FOR PREPARING PHARMACEUTICAL COMPOUNDS AND INTERMEDIATE COMPOUNDS | EGIS GYÓGYSZERGYÁR NYILÁNOSAN MŰKÖDŐ RÉSZVÉNYTÁRSASÁG (HU) | 2011-06-30 | — | — | WO | disclosed |
| WO-2011077173-A1 | IMPROVED PROCESS FOR PREPARING A PHARMACEUTICAL COMPOUND | EGIS GYÓGYSZERGYÁR NYILÁNOSAN MŰKÖDŐ RÉSZVÉNYTÁRSASÁG (HU) | 2011-06-30 | — | — | WO | disclosed |
| WO-2011029456-A1 | A PROCESS FOR MAKING PRASUGREL AND ITS INTERMEDIATES | SYNTHON BV (NL) | 2011-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130030183-A1 | PROCESS FOR PREPARING A PHARMACEUTICAL COMPOUND | CYP3A5, CYP2C19, CYP4B1 | PNMT 1623/4885KCNH2 1013/4885RYR2 1846/4885 |
| US-20120330018-A1 | PROCESS FOR PREPARING PHARMACEUTICAL COMPOUNDS AND INTERMEDIATE COMPOUNDS | CYP3A5, CYP4B1, P2RY6 | PNMT 3798/4885KCNH2 630/4885RYR2 580/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.